RxDoctor Payments Data

Jamie Tamayose, PA

Physician Assistant · Honolulu, HINPI 1053939124

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Viiv Healthcare Company at 43.0% of the total. Reporting peaked in 2022 at $1,641 and has fallen 97.9% since, to $34 in 2025. Among physician assistant clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,665in general payments, 2019–2025

Across 210 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$967
  • Johnson & Johnson$386
  • Boehringer Ingelheim$350
  • AbbVie$267
  • Indivior Inc.$256
  • plus $434 from 10 others

What the payments were for

  • Food & beverage$4,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,665 in reported general payments places this provider in the 90th percentile of 246 physician assistant providers in Hawaii.

See all physician assistant providers in Hawaii

Medicare billing

Part B allowed, 2024
$19,808
Medicare patients
182
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,166
Olanzapine14$3,244
Fluticasone Propionate57$635
Albuterol Sulfate HfaAlbuterol Sulfate20$600
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav30$336
Lisinopril19$213
Amlodipine Besylate17$208
Atorvastatin Calcium29$208
Metoprolol Succinate17$204
Azithromycin23$202
Losartan Potassium20$198
Benztropine Mesylate12$136
Mupirocin20$130
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$125
Hydrocortisone12$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$17$3,24414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 246 physician assistant providers in Hawaii.

Other physician assistant in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →